Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Within patient horizontal gene transfer dynamics of a bla<sub>NDM-7</sub> plasmid among four different bacterial species.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same author

Greater pain and functional impairment in chronic erosive hand osteoarthritis compared to treated rheumatoid arthritis: A comparative study.

Osteoarthritis and cartilage open·2025
Same author

[The MASK lift].

Annales de chirurgie plastique et esthetique·2024
Same author

Stereotactic body radiation therapy for liver metastases in oligometastatic disease.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

Role of the environment in transmission of Gram-negative bacteria in two consecutive outbreaks in a haematology-oncology department.

Infection prevention in practice·2022

Related Experiment Video

Updated: Jul 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

B cell-ablative therapy: where are we now?

A Bordron, A Mankaï, B Bendaoud

    International Journal of Immunopathology and Pharmacology
    |January 9, 2008
    PubMed
    Summary

    B cell-ablative therapy, including anti-CD20 antibodies like Rituximab, is crucial for treating various diseases. Understanding these therapies enhances immune response inhibition.

    More Related Videos

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Related Experiment Videos

    Last Updated: Jul 8, 2026

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Area of Science:

    • Immunology
    • Oncology
    • Rheumatology

    Background:

    • B cells play significant roles in lymphoproliferative disorders, autoimmune diseases, and graft rejection.
    • B cell-ablative therapy is a key treatment strategy for these conditions.
    • Anti-CD20 antibodies, such as Rituximab (RTX), are effective in B cell depletion.

    Discussion:

    • Rituximab, initially for lymphoma, is now used for other cancers, autoimmune diseases, and preventing graft rejection.
    • While generally safe, monitoring laboratory tests for RTX-treated patients are being developed.
    • The expanding applications and new anti-CD20 antibodies necessitate a deeper understanding.

    Key Insights:

    • Anti-CD20 antibodies offer a targeted approach to B cell depletion.
    • Rituximab demonstrates broad efficacy across diverse pathological settings.
    • Further research is needed to optimize the use of these therapies.

    Outlook:

    • Continued investigation into anti-CD20 antibodies will refine B cell-targeted immunotherapies.
    • Understanding B cell functions is critical for developing novel strategies to inhibit immune responses.
    • Personalized monitoring strategies may improve patient outcomes in RTX therapy.